The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
Abstract
Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through retrospective analysis of 4018 patient records. The overall incidence of drug-induced congestive heart failure was 2.2% (88 cases). The probability of incurring doxorubicin-induced congestive heart failure was related to the total dose of doxorubicin administered. There was a continuum of increasing risk as the cumulative amount of administered drug increased. A weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule. An increase in drug-related congestive heart failure was also seen with advancing patient age. Performance status, sex, race, and tumor type were not risk factors. These data will enable clinicians to better estimate the risk/benefit ratio in individual patients receiving prolonged administration of doxorubicin. They also provide a basis for the investigation of less cardiotoxic anthracycline analogues or for designing measures to prevent doxorubicin-induced cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Karnofsky, D. A., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948) · Cancer · doi:10.1002/1097-0142(194811)1:4<634::aid-cncr2820010410>3.0.co;2-l · Cited by 2,248
Covariance Analysis of Censored Survival Data
Breslow, N. (1974) · Biometrics · doi:10.2307/2529620 · Cited by 1,763
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
II. Coronary Heart Disease in the Framingham Study
Dawber, T. R., Moore, F. E., & Mann, G. V. (1957) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.47.4_pt_2.4 · Cited by 718
Analysis of Survival Data under the Proportional Hazards Model
Breslow, N. E. (1975) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402659 · Cited by 590
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
Daunomycin-induced cardiotoxicity in children and adults
Von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., & Muggia, F. M. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90315-1 · Cited by 437
Self-citationPhase II evaluation of adriamycin in human neoplasia
O'Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. H., & Bonadonna, G. (1973) · Cancer · doi:10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x · Cited by 418
BRISTOW, M. R., MASON, J. W., BILLINGHAM, M. E., & DANIELS, J. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-2-168 · Cited by 417
Benjamin, R. S., Wiernik, P. H., & Bachur, N. R. (1974) · Cancer · doi:10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m · Cited by 390
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
Minow, R. A., Benjamin, R. S., & Gottlieb, J. A. (1975) · Cited by 274
Adriamycin cardiomyopathy—risk factors
Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1397::aid-cncr2820390407>3.0.co;2-u · Cited by 251
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
TAN, C. T. C., Etcubanas, E., Wollner, N., Rosen, G., Gilladoga, A. C., Showel, J. L., Murphy, M. L., & Krakoff, I. H. (1973) · Cancer · doi:10.1002/1097-0142(197307)32:1<9::aid-cncr2820320102>3.0.co;2-6 · Cited by 235
Adriamycin Cardiotoxicity in Man
RINEHART, J. J., LEWIS, R. P., & BALCERZAK, S. P. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-475 · Cited by 190
Adriamycin and Radiation: Synergistic Cardiotoxicity
MERRILL, J., GRECO, F. A., ZIMBLER, H., BRERETON, H. D., LAMBERG, J. D., & POMEROY, T. C. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-1-122_2 · Cited by 74
Adriamycin cardiotoxicity in children.Case reports, literature review, and risk factors
Prout, M. N., Richards, M. J. S., Chung, K. J., Joo, P., & Davis, H. L. (1977) · Cancer · Cited by 52
Self-citationEchocardiographic evaluation of adriamycin cardiotoxicity in children.
Ramos, A., Meyer, R. A., Korfhagen, J. C., Wong, K. Y., & Kaplan, S. (1976) · PubMed · Cited by 36
Lack of severe hypotension with VP-16-213 administered directly lv.
Hoff, D. D. V., Layard, M., Rozencweig, M., & Muggia, F. M. (1977) · PubMed · Cited by 11
Self-citationEvaluation of cardiac function during adriamycin therapy
Burg, J. R., Moseley, H. S., Lindell, T. D., Kremkau, E. L., & Fletcher, W. S. (1974) · Journal of Surgical Oncology · doi:10.1002/jso.2930060607 · Cited by 9
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Global burden of heart failure: a comprehensive and updated review of epidemiology
Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac013 · Cited by 3,315
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Metadata
- Authors
- VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1979-11-01
- Volume
- 91
- Issue
- 5
- Pages
- 710-717
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1828224642
- Cited by
- 2,391
- References
- 25
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.